1
Philippe M Frossard: Apo AI/CIII genomic polymorphisms predictive of atherosclerosis. Biotechnology Research Partners, Ciotti & Murashige Irell & Manella, January 31, 1989: US04801531 (280 worldwide citation)

The invention offers an early detection method for atherosclerosis using genetic analysis to detect a polymorphisms shown to be correlated with this disease which are proximal to the apolipoprotein AI (apoAI) and aplipoprotein CIII (apoCIII) gene complex. All individuals with a 300 bp deletion 4 kb ...


2
Beverly Dale, Barbara Cordell: Method and compositions useful in preventing equine influenza. Biotechnology Research Partners, Irell & Manella, April 24, 1990: US04920213 (44 worldwide citation)

Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design s ...


3
Lorin K Johnson, Jeffrey J Seilhamer, Waldemar Pruzanski, Peter Vadas: Synovial phospholipases. Biotechnology Research Partners, The University of Toronto Innovations Foundation, Irell & Manella, May 28, 1991: US05019508 (31 worldwide citation)

Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to ...


4
Beverly Dale, Barbara Cordell: Methods and compositions useful in preventing equine influenza. Biotechnology Research Partners, Ciotti & Murashige, December 23, 1986: US04631191 (17 worldwide citation)

Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagluttinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design s ...


5
Philippe M Frossard: Polymorphisms related to lipid metabolism: ApoB, ApoCII, ApoE, ApoAIV. Biotechnology Research Partners, Ciotti & Murashige Irell & Manella, September 20, 1988: US04772549 (9 worldwide citation)

Polymorphisms in genes related to lipid metabolism, specifically apolipoproteins B, CII, E, and apoAIV, have been identified. Presence or absence of these polymorphisms in particular individuals may be correlated with propensity to show symptoms of atherosclerosis. Also thus correlated are two inser ...


6
Protter Andrew A, Kane John P: Novel lipoprotein-based drug-delivery systems. Biotechnology Research Partners, MURASHIGE Kate H, April 9, 1987: WO/1987/002061 (1 worldwide citation)

Pharmaceutical compositions in which the drug delivery system permits selective targeting take advantage of the amphipathic helices of apolipoproteins or binding regions of apolipoproteins for LDL receptors or both. In one embodiment, the LDL receptor binding region of an apolipoprotein, in particul ...


7
Johnson Lorin K, Laragh John H, Atlas Steven A: Polypeptide diuretique/vasodilatateur, Polypeptide diuretic/vasodilators. Biotechnology Research Partners, Biotechnology Research Associates Jv, MACRAE & CO, February 14, 1989: CA1250092

AbstractNOVEL POLYPEPTIDE DIURETIC/VASODILATORSMethods and compositions are provided for inducingnatriuresis, diuresis and vasodilatation in mammalianhosts by administering auriculin or a synthetic analogof auriculin to said host.


8
Johnson Lorin K, Longenecker John P: Proteine anti-inflammatoire inhibitrice de la phospholipase humaine, Human anti-inflammatory phospholipase inhibitor protein. Biotechnology Research Partners, BATTISON WILLIAMS DUPUIS, October 8, 1991: CA1290267

ABSTRACT Cloning and expression of the gene encodinghuman phosphlipase inhibitory protein (hPIP) permitsproduction of an anti-inflammatory protein in practicalquantities using recombinant techniques.


9
Johnson Lorin K, Mccarthy Brian J: Expression de nouveaux composes diuretiques/vasodilateurs par adn recombinant, Recombinant dna expression of novel diuretic/vasodilator compounds. Biotechnology Research Partners, California Biotechnology, MACRAE & CO, December 15, 1998: CA1340264

Methods and compositions are provided for inducingnatriuresis, diuresis and vasodilatation in mammalianhosts by administering pre-proauriculin to said host.Also provided are methods and compositions for theproduction of auriculin, proauriculin andpre-pro-auriculin utilizing DNA sequences.


10
Dale Beverly, Cordell Barbara: Methods and compositions useful in preventing equine influenza. Biotechnology Research Partners, MURASHIGE Kate H, December 31, 1986: WO/1986/007593

Recombinant vaccines for immunizing horses against equine influenza virus (EIV). The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic pepti ...